Enliven Therapeutics Inc. (ELVN) shares rocketed higher on Thursday, and it's not hard to see why. The clinical-stage biotech company delivered exactly what investors want to hear: promising early data that suggests its experimental drug might actually work. Trading volume hit 6.61 million shares, more than ten times the typical daily average of 631,520 shares.
The excitement centers on initial results from the ongoing Phase 1b ENABLE trial of ELVN-001, which targets patients with chronic myeloid leukemia (CML) that has either relapsed, proven resistant to existing treatments, or caused intolerable side effects with available tyrosine kinase inhibitors.
The Numbers Look Good
As of the December 22, 2025 data cutoff, 60 heavily pre-treated patients had enrolled in the trial. These weren't easy cases—these were patients who had already cycled through multiple treatment options.
In the mature 80 mg daily dose cohort of 19 patients (all evaluable for efficacy by 24 weeks), the drug achieved a 38% major molecular response rate and 16% deep molecular response rate. Those figures stack up favorably against precedent Phase 1 trials of approved BCR::ABL1 TKIs, including Novartis AG's (NVS) Scemblix (asciminib), which is already on the market.
The randomized cohorts testing 60 mg and 120 mg doses showed even more encouraging results. Among those 41 patients, major molecular response rates hit 53%, while deep molecular response rates reached 35%. Perhaps most impressive: every evaluable patient who entered the trial already in major molecular response either maintained or improved their response—a 100% success rate on that metric.
Safety Profile Holds Up
The drug showed clinical activity across the tested dose range of 60 mg to 120 mg daily, with no clear correlation between higher doses and better efficacy or worse side effects. That's actually good news—it suggests the company has flexibility in choosing an optimal dose for later-stage trials.
ELVN-001 continued to demonstrate favorable safety and tolerability across all evaluated doses. The safety profile remained consistent with previously reported data, with no maximum tolerated dose identified and no new safety signals emerging. In drug development, "boring" safety data is often the best kind of safety data.
Enliven plans to initiate the ENABLE-2 Phase 3 trial of ELVN-001 in the second half of 2026, marking a significant step toward potential regulatory approval.
Enliven Therapeutics shares traded up 50.42% at $23.27 at the time of publication on Thursday.
